SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-028066
Filing Date
2023-06-02
Accepted
2023-06-02 16:30:42
Documents
13
Period of Report
2023-06-01
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc20053954_8k.htm   iXBRL 8-K 27973
2 EXHIBIT 3.1 brhc20053954_ex3-1.htm EX-3.1 10386
  Complete submission text file 0001140361-23-028066.txt   179915

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ocup-20230601.xsd EX-101.SCH 3865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20230601_lab.xml EX-101.LAB 23291
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20230601_pre.xml EX-101.PRE 16552
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc20053954_8k_htm.xml XML 4248
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 23989317
SIC: 2834 Pharmaceutical Preparations